{"id":994,"date":"2026-06-21T13:01:16","date_gmt":"2026-06-21T13:01:16","guid":{"rendered":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/"},"modified":"2026-06-21T13:01:16","modified_gmt":"2026-06-21T13:01:16","slug":"choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics","status":"publish","type":"post","link":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/","title":{"rendered":"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics"},"content":{"rendered":"<p data-blockid=\"replaceWithId\" data-depth=\"0\">Navigating the US FDA regulatory pathway and the Health Canada regulatory pathway can feel like solving a puzzle without the picture on the box. Choosing the wrong route delays approval, inflates costs, and drains resources. This guide breaks down the critical differences\u2014like 510(k) vs De Novo and NDA vs ANDA\u2014to help you select the fastest, lowest-risk path for your product. Let\u2019s map a clear, compliant course to market success. <a href=\"https:\/\/www.fda.gov\/medical-devices\/device-advice-comprehensive-regulatory-assistance\/how-study-and-market-your-device\" target=\"_blank\">Learn more<\/a>.<\/p>\n<h2 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">Navigating Regulatory Pathways<\/h2>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Understanding the right regulatory pathways is crucial for compliance and market success. Let&#8217;s explore how choosing the right path can streamline your approval process.<\/p>\n<h3 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">Understanding US FDA Pathways<\/h3>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">The US FDA offers multiple pathways for product approval, each suited to different needs. Understanding these can save time and avoid costly mistakes.<\/p>\n<ul data-blockid=\"replaceWithId\" data-markerformat=\"circle\" data-type=\"unordered_list\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1; list-style: none\">\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>510(k) and De Novo:<\/strong> These pathways are for medical devices. The 510(k) is for devices similar to those already approved, while De Novo is for new types of devices. For more details, explore <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8920055\/\" target=\"_blank\">this resource on FDA pathways<\/a>.<\/p>\n<\/li>\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>NDA vs ANDA:<\/strong> For drugs, the New Drug Application (NDA) is used for new drugs, while the Abbreviated New Drug Application (ANDA) is for generics.<\/p>\n<\/li>\n<\/ul>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Knowing which pathway applies to your product ensures faster approval. Most companies benefit from understanding these distinctions early on.<\/p>\n<h3 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">Health Canada Pathway Basics<\/h3>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Navigating Health Canada&#8217;s regulatory environment requires understanding its distinct pathways. Here\u2019s how these pathways differ:<\/p>\n<ul data-blockid=\"replaceWithId\" data-markerformat=\"circle\" data-type=\"unordered_list\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1; list-style: none\">\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Medical Device Licensing:<\/strong> Devices require either a Medical Device License (MDL) or a Medical Device Establishment License (MDEL).<\/p>\n<\/li>\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Natural Health Products:<\/strong> These require a Natural Health Product license, which involves meeting specific safety and efficacy standards. More on this can be found <a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medical-devices.html\" target=\"_blank\">here<\/a>.<\/p>\n<\/li>\n<\/ul>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Choosing the right pathway helps in avoiding delays and compliance issues. The specifics of your product dictate the best route forward.<\/p>\n<h3 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">Key Differences: US vs Canada<\/h3>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Key differences between US FDA and Health Canada pathways significantly impact regulatory strategies.<\/p>\n<ul data-blockid=\"replaceWithId\" data-markerformat=\"circle\" data-type=\"unordered_list\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1; list-style: none\">\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Approval Process:<\/strong> The US FDA tends to have more structured processes, while Health Canada focuses on safety and efficacy.<\/p>\n<\/li>\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Documentation:<\/strong> The documentation varies, with Canada requiring specific bilingual submissions.<\/p>\n<\/li>\n<\/ul>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Understanding these differences is key in crafting an effective regulatory strategy and ensuring compliance in both markets.<\/p>\n<h2 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">Product Classification and Jurisdiction<\/h2>\n<p><img decoding=\"async\" data-blockid=\"replaceWithId\" data-float=\"center\" data-href=\"\" src=\"https:\/\/blaze-media-uploads-for-dev.s3.us-west-1.amazonaws.com\/nano_banana_generated-4da069ba0f02a35eb254.jpg\" alt=\"\" title=\"\" data-media-file-id=\"F0vUKl3CtKwLcR8kXKHSyIpxoolvsutl\" style=\"max-width: 100%;height: auto;display: block;margin: 0 auto;\"><\/p>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Classifying your product correctly is critical for determining the right regulatory pathway. This section breaks down the classification essentials.<\/p>\n<h3 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">Drug, Device, and Biologic Mapping<\/h3>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Product classification determines the regulatory requirements your product must meet. Here\u2019s a guide:<\/p>\n<ul data-blockid=\"replaceWithId\" data-markerformat=\"circle\" data-type=\"unordered_list\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1; list-style: none\">\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Drugs:<\/strong> Generally require an NDA or ANDA in the US. In Canada, they need a Drug Identification Number (DIN).<\/p>\n<\/li>\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Devices:<\/strong> Classified based on risk, with different submission requirements for each class. <a href=\"https:\/\/www.ipdanalytics.com\/post\/understanding-us-regulatory-pathways-drug-products-8\" target=\"_blank\">Read more about device classification<\/a>.<\/p>\n<\/li>\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Biologics:<\/strong> Have distinct pathways due to their complexity and innovation needs.<\/p>\n<\/li>\n<\/ul>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Proper classification ensures products meet specific regulatory requirements and align with market demands.<\/p>\n<h3 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">NHP and Cosmetic Pathways<\/h3>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Natural Health Products (NHPs) and cosmetics have unique pathways, especially in Canada.<\/p>\n<ul data-blockid=\"replaceWithId\" data-markerformat=\"circle\" data-type=\"unordered_list\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1; list-style: none\">\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>NHPs:<\/strong> Require site licensing and meet specific evidence requirements to gain approval.<\/p>\n<\/li>\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Cosmetics:<\/strong> Must comply with labeling regulations and, in Canada, require Cosmetic Notification.<\/p>\n<\/li>\n<\/ul>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Correctly classifying NHPs and cosmetics avoids potential compliance issues and accelerates market entry.<\/p>\n<h3 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">Combination Product Considerations<\/h3>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Combination products, such as those combining drugs and devices, face unique regulatory challenges.<\/p>\n<ul data-blockid=\"replaceWithId\" data-markerformat=\"circle\" data-type=\"unordered_list\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1; list-style: none\">\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Pathway Selection:<\/strong> Depends on the product&#8217;s primary mode of action.<\/p>\n<\/li>\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Regulatory Coordination:<\/strong> Requires aligning with both drug and device regulations.<\/p>\n<\/li>\n<\/ul>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Understanding these considerations is crucial for efficient submission and approval.<\/p>\n<h2 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">Preparing for Submission<\/h2>\n<p><img decoding=\"async\" data-blockid=\"replaceWithId\" data-float=\"center\" data-href=\"\" src=\"https:\/\/blaze-media-uploads-for-dev.s3.us-west-1.amazonaws.com\/nano_banana_generated-1127fdd0db4e704c1a0a.png\" alt=\"\" title=\"\" data-media-file-id=\"zmlCaVkM4xaQbXagpbsVLwTL7MdJB5Tu\" style=\"max-width: 100%;height: auto;display: block;margin: 0 auto;\"><\/p>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Preparation is key to a successful regulatory submission. This section guides you through essential steps and requirements.<\/p>\n<h3 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">Evidence and Data Requirements<\/h3>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Regulatory submissions require robust evidence and data to support product claims.<\/p>\n<ul data-blockid=\"replaceWithId\" data-markerformat=\"circle\" data-type=\"unordered_list\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1; list-style: none\">\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Data Collection:<\/strong> Includes clinical data and product testing results.<\/p>\n<\/li>\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Documentation Standards:<\/strong> Must meet specific format and content requirements for each regulatory body.<\/p>\n<\/li>\n<\/ul>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Collecting comprehensive evidence upfront supports a smoother submission process.<\/p>\n<h3 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">Crafting a Submission Blueprint<\/h3>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">A well-crafted blueprint outlines the steps needed for a successful submission.<\/p>\n<ul data-blockid=\"replaceWithId\" data-markerformat=\"circle\" data-type=\"unordered_list\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1; list-style: none\">\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Regulatory Strategy:<\/strong> Defines the submission pathway and timelines.<\/p>\n<\/li>\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Documentation Plan:<\/strong> Ensures all necessary documents are prepared accurately.<\/p>\n<\/li>\n<\/ul>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">A strategic blueprint ensures clarity and organization, reducing the risk of delays.<\/p>\n<h3 data-blockid=\"replaceWithId\" data-depth=\"0\" id=\"replaceWithId\">Post-Approval Compliance Essentials<\/h3>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Compliance doesn\u2019t stop at approval. Post-approval requirements ensure ongoing safety and efficacy.<\/p>\n<ul data-blockid=\"replaceWithId\" data-markerformat=\"circle\" data-type=\"unordered_list\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1; list-style: none\">\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Ongoing Monitoring:<\/strong> Includes post-market surveillance and reporting.<\/p>\n<\/li>\n<li data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\">\n<p data-blockid=\"replaceWithId\" data-depth=\"0\" style=\"margin-top: 0; margin-bottom: 0; padding-top: 0; padding-bottom: 0; line-height: 1\"><strong>Regulatory Updates:<\/strong> Keeping abreast of changes in regulations to maintain compliance.<\/p>\n<\/li>\n<\/ul>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">Staying compliant post-approval safeguards against recalls and regulatory penalties.<\/p>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">By understanding these pathways and preparing effectively, you can navigate the regulatory landscape confidently and efficiently.<\/p>\n<p data-blockid=\"replaceWithId\" data-depth=\"0\">\n","protected":false},"excerpt":{"rendered":"<p>This guide clarifies US FDA and Health Canada regulatory pathways for pharma, devices, NHPs, and cosmetics to ensure correct classification, streamlined submissions, and ongoing compliance.<\/p>\n","protected":false},"author":1,"featured_media":993,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[79],"tags":[1426,1412,1419,892,1126,363,1418,1124,1344,1423,1424,536,1411,1130,1417,1416,1415,1413,916,537,1414,978,1086,1427,1421,1422,1425,554,1420,1410],"class_list":["post-994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-avinash-k-arora","tag-510k-submission-support","tag-510k-vs-de-novo","tag-combination-product-pathway","tag-cosmetic-labeling-compliance","tag-cosmetic-notification-canada","tag-de-novo-classification-request","tag-device-classification-us-and-canada","tag-din-application-support","tag-drug-identification-number-din-2","tag-ectd-submission-support","tag-fda-drug-listing-and-registration","tag-health-canada-nnhpd","tag-health-canada-regulatory-pathway","tag-market-entry-us-and-canada","tag-medical-device-establishment-license-mdel","tag-medical-device-license-mdl-2","tag-natural-health-product-license","tag-nda-vs-anda","tag-nhp-evidence-requirements","tag-nhp-site-license","tag-notice-of-compliance-canada","tag-otc-monograph-compliance","tag-pma-requirements","tag-pma-submission-consulting","tag-predicate-device-search","tag-q-sub-fda-pre-submission","tag-quality-system-requirements-gmp-qms","tag-regulatory-strategy-consulting","tag-software-as-a-medical-device-samd-2","tag-us-fda-regulatory-pathway"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.8 - aioseo.com -->\n\t<meta name=\"description\" content=\"This guide clarifies US FDA and Health Canada regulatory pathways for pharma, devices, NHPs, and cosmetics to ensure correct classification, streamlined submissions, and ongoing compliance.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"admin\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.8\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Arora 297 Consultancy - Unlocking Insights, Empowering Success: Your Trusted Source for Regulatory Guidance and Compliance\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics - Arora 297 Consultancy\" \/>\n\t\t<meta property=\"og:description\" content=\"This guide clarifies US FDA and Health Canada regulatory pathways for pharma, devices, NHPs, and cosmetics to ensure correct classification, streamlined submissions, and ongoing compliance.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.arora297consultancy.com\/assets\/media\/general\/logo.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.arora297consultancy.com\/assets\/media\/general\/logo.png\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-06-21T13:01:16+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-06-21T13:01:16+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/consultingwithoutboundaries\/\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics - Arora 297 Consultancy\" \/>\n\t\t<meta name=\"twitter:description\" content=\"This guide clarifies US FDA and Health Canada regulatory pathways for pharma, devices, NHPs, and cosmetics to ensure correct classification, streamlined submissions, and ongoing compliance.\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.arora297consultancy.com\/assets\/media\/general\/logo.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#blogposting\",\"name\":\"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics - Arora 297 Consultancy\",\"headline\":\"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics\",\"author\":{\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/author\\\/admin\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/featured-image-1782046867.png\",\"width\":1200,\"height\":896},\"datePublished\":\"2026-06-21T13:01:16+00:00\",\"dateModified\":\"2026-06-21T13:01:16+00:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#webpage\"},\"articleSection\":\"Regulatory Insights, 510(k) submission support, 510(k) vs De Novo, Combination product pathway, cosmetic labeling compliance, Cosmetic notification Canada, De Novo classification request, Device classification US and Canada, DIN application support, Drug Identification Number DIN, eCTD submission support, FDA drug listing and registration, Health Canada NNHPD, Health Canada regulatory pathway, Market entry US and Canada, Medical Device Establishment License MDEL, Medical Device License MDL, Natural Health Product license, NDA vs ANDA, NHP evidence requirements, NHP site license, Notice of Compliance Canada, OTC monograph compliance, PMA requirements, PMA submission consulting, Predicate device search, Q-Sub FDA Pre-Submission, Quality system requirements GMP QMS, regulatory strategy consulting, Software as a Medical Device SaMD, US FDA regulatory pathway\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/category\\\/arora-297-consultancy\\\/#listItem\",\"name\":\"Arora 297 Consultancy\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/category\\\/arora-297-consultancy\\\/#listItem\",\"position\":2,\"name\":\"Arora 297 Consultancy\",\"item\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/category\\\/arora-297-consultancy\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/category\\\/arora-297-consultancy\\\/avinash-k-arora\\\/#listItem\",\"name\":\"Regulatory Insights\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/category\\\/arora-297-consultancy\\\/avinash-k-arora\\\/#listItem\",\"position\":3,\"name\":\"Regulatory Insights\",\"item\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/category\\\/arora-297-consultancy\\\/avinash-k-arora\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#listItem\",\"name\":\"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/category\\\/arora-297-consultancy\\\/#listItem\",\"name\":\"Arora 297 Consultancy\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#listItem\",\"position\":4,\"name\":\"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/category\\\/arora-297-consultancy\\\/avinash-k-arora\\\/#listItem\",\"name\":\"Regulatory Insights\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/#organization\",\"name\":\"Arora Consultancy\",\"description\":\"Unlocking Insights, Empowering Success: Your Trusted Source for Regulatory Guidance and Compliance\",\"url\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/\",\"telephone\":\"+15194985957\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.arora297consultancy.com\\\/assets\\\/media\\\/general\\\/logo.png\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/consultingwithoutboundaries\\\/\",\"https:\\\/\\\/www.instagram.com\\\/arora297consultancy\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/arora-297-consultancy\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/author\\\/admin\\\/#author\",\"url\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/author\\\/admin\\\/\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9c4b4c0b5727c4eaa4bbf02b476c099d4d7bb4a1fdceeafb6890a386e37d0bc6?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"admin\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#webpage\",\"url\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/\",\"name\":\"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics - Arora 297 Consultancy\",\"description\":\"This guide clarifies US FDA and Health Canada regulatory pathways for pharma, devices, NHPs, and cosmetics to ensure correct classification, streamlined submissions, and ongoing compliance.\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/author\\\/admin\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/author\\\/admin\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/featured-image-1782046867.png\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#mainImage\",\"width\":1200,\"height\":896},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\\\/#mainImage\"},\"datePublished\":\"2026-06-21T13:01:16+00:00\",\"dateModified\":\"2026-06-21T13:01:16+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/\",\"name\":\"Blog\",\"description\":\"Unlocking Insights, Empowering Success: Your Trusted Source for Regulatory Guidance and Compliance\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/arora297consultancy.com\\\/blog\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics - Arora 297 Consultancy","description":"This guide clarifies US FDA and Health Canada regulatory pathways for pharma, devices, NHPs, and cosmetics to ensure correct classification, streamlined submissions, and ongoing compliance.","canonical_url":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#blogposting","name":"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics - Arora 297 Consultancy","headline":"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics","author":{"@id":"https:\/\/arora297consultancy.com\/blog\/author\/admin\/#author"},"publisher":{"@id":"https:\/\/arora297consultancy.com\/blog\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/arora297consultancy.com\/blog\/wp-content\/uploads\/2026\/06\/featured-image-1782046867.png","width":1200,"height":896},"datePublished":"2026-06-21T13:01:16+00:00","dateModified":"2026-06-21T13:01:16+00:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#webpage"},"isPartOf":{"@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#webpage"},"articleSection":"Regulatory Insights, 510(k) submission support, 510(k) vs De Novo, Combination product pathway, cosmetic labeling compliance, Cosmetic notification Canada, De Novo classification request, Device classification US and Canada, DIN application support, Drug Identification Number DIN, eCTD submission support, FDA drug listing and registration, Health Canada NNHPD, Health Canada regulatory pathway, Market entry US and Canada, Medical Device Establishment License MDEL, Medical Device License MDL, Natural Health Product license, NDA vs ANDA, NHP evidence requirements, NHP site license, Notice of Compliance Canada, OTC monograph compliance, PMA requirements, PMA submission consulting, Predicate device search, Q-Sub FDA Pre-Submission, Quality system requirements GMP QMS, regulatory strategy consulting, Software as a Medical Device SaMD, US FDA regulatory pathway"},{"@type":"BreadcrumbList","@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/arora297consultancy.com\/blog#listItem","position":1,"name":"Home","item":"https:\/\/arora297consultancy.com\/blog","nextItem":{"@type":"ListItem","@id":"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/#listItem","name":"Arora 297 Consultancy"}},{"@type":"ListItem","@id":"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/#listItem","position":2,"name":"Arora 297 Consultancy","item":"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/","nextItem":{"@type":"ListItem","@id":"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/avinash-k-arora\/#listItem","name":"Regulatory Insights"},"previousItem":{"@type":"ListItem","@id":"https:\/\/arora297consultancy.com\/blog#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/avinash-k-arora\/#listItem","position":3,"name":"Regulatory Insights","item":"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/avinash-k-arora\/","nextItem":{"@type":"ListItem","@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#listItem","name":"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics"},"previousItem":{"@type":"ListItem","@id":"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/#listItem","name":"Arora 297 Consultancy"}},{"@type":"ListItem","@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#listItem","position":4,"name":"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics","previousItem":{"@type":"ListItem","@id":"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/avinash-k-arora\/#listItem","name":"Regulatory Insights"}}]},{"@type":"Organization","@id":"https:\/\/arora297consultancy.com\/blog\/#organization","name":"Arora Consultancy","description":"Unlocking Insights, Empowering Success: Your Trusted Source for Regulatory Guidance and Compliance","url":"https:\/\/arora297consultancy.com\/blog\/","telephone":"+15194985957","logo":{"@type":"ImageObject","url":"https:\/\/www.arora297consultancy.com\/assets\/media\/general\/logo.png","@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#organizationLogo"},"image":{"@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#organizationLogo"},"sameAs":["https:\/\/www.facebook.com\/consultingwithoutboundaries\/","https:\/\/www.instagram.com\/arora297consultancy\/","https:\/\/www.linkedin.com\/company\/arora-297-consultancy\/"]},{"@type":"Person","@id":"https:\/\/arora297consultancy.com\/blog\/author\/admin\/#author","url":"https:\/\/arora297consultancy.com\/blog\/author\/admin\/","name":"admin","image":{"@type":"ImageObject","@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/9c4b4c0b5727c4eaa4bbf02b476c099d4d7bb4a1fdceeafb6890a386e37d0bc6?s=96&d=mm&r=g","width":96,"height":96,"caption":"admin"}},{"@type":"WebPage","@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#webpage","url":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/","name":"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics - Arora 297 Consultancy","description":"This guide clarifies US FDA and Health Canada regulatory pathways for pharma, devices, NHPs, and cosmetics to ensure correct classification, streamlined submissions, and ongoing compliance.","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/arora297consultancy.com\/blog\/#website"},"breadcrumb":{"@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#breadcrumblist"},"author":{"@id":"https:\/\/arora297consultancy.com\/blog\/author\/admin\/#author"},"creator":{"@id":"https:\/\/arora297consultancy.com\/blog\/author\/admin\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/arora297consultancy.com\/blog\/wp-content\/uploads\/2026\/06\/featured-image-1782046867.png","@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#mainImage","width":1200,"height":896},"primaryImageOfPage":{"@id":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/#mainImage"},"datePublished":"2026-06-21T13:01:16+00:00","dateModified":"2026-06-21T13:01:16+00:00"},{"@type":"WebSite","@id":"https:\/\/arora297consultancy.com\/blog\/#website","url":"https:\/\/arora297consultancy.com\/blog\/","name":"Blog","description":"Unlocking Insights, Empowering Success: Your Trusted Source for Regulatory Guidance and Compliance","inLanguage":"en-US","publisher":{"@id":"https:\/\/arora297consultancy.com\/blog\/#organization"}}]},"og:locale":"en_US","og:site_name":"Arora 297 Consultancy - Unlocking Insights, Empowering Success: Your Trusted Source for Regulatory Guidance and Compliance","og:type":"article","og:title":"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics - Arora 297 Consultancy","og:description":"This guide clarifies US FDA and Health Canada regulatory pathways for pharma, devices, NHPs, and cosmetics to ensure correct classification, streamlined submissions, and ongoing compliance.","og:url":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/","og:image":"https:\/\/www.arora297consultancy.com\/assets\/media\/general\/logo.png","og:image:secure_url":"https:\/\/www.arora297consultancy.com\/assets\/media\/general\/logo.png","article:published_time":"2026-06-21T13:01:16+00:00","article:modified_time":"2026-06-21T13:01:16+00:00","article:publisher":"https:\/\/www.facebook.com\/consultingwithoutboundaries\/","twitter:card":"summary_large_image","twitter:title":"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics - Arora 297 Consultancy","twitter:description":"This guide clarifies US FDA and Health Canada regulatory pathways for pharma, devices, NHPs, and cosmetics to ensure correct classification, streamlined submissions, and ongoing compliance.","twitter:image":"https:\/\/www.arora297consultancy.com\/assets\/media\/general\/logo.png"},"aioseo_meta_data":[],"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/arora297consultancy.com\/blog\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/\" title=\"Arora 297 Consultancy\">Arora 297 Consultancy<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/avinash-k-arora\/\" title=\"Regulatory Insights\">Regulatory Insights<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tChoosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/arora297consultancy.com\/blog"},{"label":"Arora 297 Consultancy","link":"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/"},{"label":"Regulatory Insights","link":"https:\/\/arora297consultancy.com\/blog\/category\/arora-297-consultancy\/avinash-k-arora\/"},{"label":"Choosing the Right Regulatory Pathway in the US and Canada: A Practical Guide for Pharma, Medical Devices, NHPs, and Cosmetics","link":"https:\/\/arora297consultancy.com\/blog\/choosing-the-right-regulatory-pathway-in-the-us-and-canada-a-practical-guide-for-pharma-medical-devices-nhps-and-cosmetics\/"}],"_links":{"self":[{"href":"https:\/\/arora297consultancy.com\/blog\/wp-json\/wp\/v2\/posts\/994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arora297consultancy.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arora297consultancy.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arora297consultancy.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/arora297consultancy.com\/blog\/wp-json\/wp\/v2\/comments?post=994"}],"version-history":[{"count":0,"href":"https:\/\/arora297consultancy.com\/blog\/wp-json\/wp\/v2\/posts\/994\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/arora297consultancy.com\/blog\/wp-json\/wp\/v2\/media\/993"}],"wp:attachment":[{"href":"https:\/\/arora297consultancy.com\/blog\/wp-json\/wp\/v2\/media?parent=994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arora297consultancy.com\/blog\/wp-json\/wp\/v2\/categories?post=994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arora297consultancy.com\/blog\/wp-json\/wp\/v2\/tags?post=994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}